Qardio

Executive Summary

Qardio is a San Francisco-based digital health company specializing in cardiovascular monitoring and management. Since its founding in 2012, the company has developed a suite of clinically validated, connected devices—including blood pressure monitors, ECG, heart rate trackers, and body composition scales—that integrate with an AI-driven app and platform. This ecosystem enables patients and healthcare professionals to remotely track chronic conditions such as hypertension and arrhythmias, improving outcomes while reducing costs. By leveraging artificial intelligence for data analysis and personalized insights, Qardio positions itself at the intersection of consumer health tech and clinical-grade remote monitoring. The company's focus aligns with the growing demand for telehealth and home-based care, particularly for cardiovascular diseases, which remain the leading cause of death globally. While Qardio has not disclosed fundraising or valuation, its products are available on major e-commerce platforms and through healthcare providers, suggesting steady market penetration. However, as a private company without recent funding announcements, Qardio may face challenges in scaling amid competition from established players like Withings and Omron, as well as emerging digital health startups. The company's ability to secure regulatory clearances for new algorithms or forge strategic partnerships with health systems will be critical to its future growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation blood pressure monitor with enhanced AI diagnostics65% success
• Q4 2026FDA clearance for a new arrhythmia detection algorithm integrated into ECG device55% success
• Q2 2027Partnership with a major U.S. health system for remote patient monitoring program45% success